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T-cell Receptor Gamma (TRG) rearrangements are commonly used to detect clonal lymphoproliferations in hematopathology, since
they are rearranged in virtually all T lymphocytes and have a relatively limited recombinatorial repertoire, which reduces the risk of false
negative results, at the cost of potential false positivity. We developed an initial one-tube, 2-ﬂuorochrome EuroClonality TRG PCR
multiplex (TRG-1T-2F) which was compared to the original 2-tube, 2-ﬂuorochrome EuroClonality/BIOMED-2 TRG PCR (TRG-2T-2F)
and a commercial Invivoscribe one-tube, one-ﬂuorochrome kit (IVS-1T-1F) on a series of 239 samples, including both T-cell
malignancies and reactive cases. This initial assay yielded discrepant results between the 10 participating EuroClonality laboratories
when using 2 ﬂuorochromes, leading to adoption of a ﬁnal single color EuroClonality strategy (TRG-1T-1F). Compared to TRG-2T-2F,
both TRG-1T-1F and IVS-1T-1F demonstrated easier interpretation and a lower risk of false positive from minor peaks in dispersed
repertoires. Both generate smaller fragments and as such are likely to be better adapted to analysis of formalin-ﬁxed parafﬁn-
embedded (FFPE) tissue samples. Their differential performance was mainly explained by (i) superposition of biallelic rearrangements
with IVS-1T-1F, due to more extensive overlapping of the repertoires and (ii) intentional omission of the TRGJP primer in TRG-1T-1F,
in order to avoid the potential risk of confusion of consensus TRG V9-JP normal rearrangements with a pathological clone.B, DL, EB, MB, PAE, PG, MH, PV, PJG, AWL, EAM, and FD are members of
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1Introduction
The tremendous diversity of antigen receptors stems from genetic
recombination occurring during early stages of lymphopoiesis.
Random assembly of the many variable (V), diversity (D), and
joining (J) genes, and pairing of both chains of these hetero-
dimeric receptors provide substantial combinatorial diversity,
which is considerably enhanced by the so-called junctional
diversity.1,2 Hence, rearrangements of IG or TR genes constitute
unique, cell-speciﬁc, molecular markers for B and T lymphocytes,
respectively. As, in most instances, tumor cells are the progeny of
a single transformed malignant cell, analysis of antigen receptor
gene rearrangements by PCR and capillary electrophoresis
(GeneScan) sizing provides a method for clonality assessment
of lymphoid proliferations.3–6
Analysis of T-cell lineage clonality is particularly prone to
interpretation issues as clonal rearrangements can be detected in
non-malignant conditions including those associated with
perturbed and restricted immune repertoires, such as chronic
infection,7,8 auto-immune disease,9–11 bone marrow transplan-
tation12 as well as in elderly individuals.13,14 Finally, ampliﬁca-
tion of IG/TR gene rearrangements from rare B or T-cells in a
sample containing few lymphocytes can generate a seemingly
clonal proﬁle, termed pseudoclonality.15
Standardization of the molecular detection of lymphoid
clonality was achieved almost 15 years ago within a European
consortium involving over 45 laboratories (BIOMED-2Concerted
Action BMH4 CT98–3936, hereafter named EuroClonality).16
This resulted in a series of robust and highly reliable, polymerase
M. Armand et al. A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell Clonalitychain reaction (PCR)-based assays, along with interpretation
guidelines,which are nowwidely used in diagnostic laboratories.15
TRG genes have been a preferential target for T-lineage
clonality as (i) they are rearranged in all but the most immature
T lymphocytes of both the TR gd and ab lineages, and (ii) the
limited number of TRGV and TRGJ genes allows their
ampliﬁcation with a small set of primers. The EuroClonality/Figure 1. GeneScan analysis of the same polyclonal sample with all PCR as
1F; (E) TRG-1T-JPgr with identical FAM (blue) labeling of the TRGJP1/2 and TRGJ1
1T-1F with identical FAM labeling of theTRGJP1/2 and TRGJ1/2 primers, optimis
2BIOMED-2 TRG assay was designed as 2 multiplex PCR tubes,
each with 2 ﬂuorochromes, hereafter termed TRG-2T-2F. No
TRGJP primer was included in order to avoid ampliﬁcation of
invariant, “canonical” TRGV9-TRGJP rearrangements, thus
preventing their false identiﬁcation as a clonal product.17 TRGV
primers were positioned in such a way that they allowed TRGV
gene identiﬁcation based on the size of the PCR products (Fig. 1).says. (A) TRG-2T-2F tube A; (B) TRG-2T-2F tube B; (C) TRG-1T-2F; (D) IVS-1T-
/2 primers and addition of an HEX-labeled TRGJPgreen (JPgr) primer; (F) TRG-
ed PCR conditions, and no TRGJP primer.
(2019) 3:3 www.hemaspherejournal.comLabeling the 2 reverse primers with different ﬂuorochromes also
permitted distinction of TRGJ1/2 and TRGJP1/2 genes using
GeneScan analysis. Therefore, in addition to clonality assess-
ment, this assay could be used for partial TRG genotyping of
malignant T-cell populations, a useful feature for subsequent
minimal residual disease (MRD) analysis, in particular for acute
lymphoblastic leukemia samples.18
A drawback of this approach in the context of diagnostic
hematopathology is that the PCR products are scattered over a
wide size range and cluster according to distinct TRGV-TRGJ
combinations. As a consequence, polyclonal T lymphocytes
demonstrating rare TRGV-TRGJ rearrangements, for example
those using TRGV11, are at risk of being mistaken for a clonal
population, due to the absence of a polyclonal background for
that type of rearrangement (Fig. 1B).
With these considerations in mind, the EuroClonality consor-
tium undertook to develop an alternative TRG multiplex PCR
assaywith the following speciﬁcations: (i) to regroupPCRproducts
withina limited size rangebymodifyingprimer positions inorder to
avoid over-interpretation of minor peaks of unknown signiﬁcance,
(ii) to combine all primers within a single tube, (iii) to generate
relatively short PCR products (<200bp) to facilitate analysis of
FFPE samples in diagnostic pathology laboratories. Several one-
tubeTRGassays havebeen described 19–23 andone is commercially
available from the Invivoscribe (hereafter termed IVS) company. In
the present study, we evaluated this new one-tube EuroClonality
TRG-1T-2F assay as well as the one-tube assay from IVS (IVS-1T-
1F) on a large series of T-cell malignancies and reactive samples, in
comparison with the conventional TRG-2T-2F assay.Results
Primer positions and amplicon sizes of the different
TRG PCR assays
Typical GeneScan proﬁles obtained on a polyclonal sample are
shown for all tested TRG multiplex PCR assays in Figure 1. PCR
products obtained with TRG-2T-2F primers were dispersed over
8 size ranges, that is, 145 to 255bp for tube A and 80 to 220bp
for tube B, as described.16 The TRG-1T-2F assay resulted in 2
distinct overlapping Gaussian curves depending on TRGJ usage,
with a 140 to 200bp range. A single Gaussian curve, ranging
from 160bp to 210bp was observed with the IVS-1T-1F system.Table 1
Inter-laboratory discrepancies of the different TRG PCR assays.
PCR assay
Cases with different
peak intensity
∗
between the
paired laboratories (n= )
Cases with different number of
peaks between the paired
laboratories (n= )Sensitivity of the various TRG PCR assays
Analytical sensitivity was determined by testing DNA dilutions
(10%, 5%, and 1%) from 7 human T-cell lines in peripheral
blood mononuclear cells from a healthy donor. Depending on the
position of the clonal rearrangement(s) within the Gaussian
curve of polyclonal peaks, the sensitivity threshold varied from
1% to 10% (SDC Table 1, Supplemental Digital Content, http://
links.lww.com/HS/A35). Two cell lines (HSB2 and Jurkat) had a
slightly increased sensitivity with the TRG-2T-2F PCR since their
clonal rearrangements were situated outside the bulk of the
Gaussian distribution of polyclonal rearrangements, particularly
evident with the more dispersed repertoires in this assay.TRG-2T-2F 5 7
TRG-1T-2F 10 1
IVS-1T-1F 1 3
Total 16 11
∗
Different intensities relative to other clonal peaks and/or the polyclonal peaks in the sample.Inter-laboratory comparison of the GeneScan
proﬁles of the different TRG PCR assays
GeneScan proﬁles for all 3 PCR assays were ﬁrst compared
between the paired laboratories and led to concordant3interpretations in both laboratories in 205/239 (86%) cases. In
further 7 cases, the GeneScan proﬁles were actually similar, but
minor peaks of unclear signiﬁcance with the TRG-2T-2F PCR
(data not shown) were interpreted differently in the 2 laborato-
ries. Joint re-analysis of the GeneScan proﬁles enabled the 2
laboratories to systematically come to a consensus, essentially by
not over-interpreting minor peaks.
In the remaining 27/239 cases (11%), the GeneScan proﬁles
differed between paired laboratories, either regarding the
intensity of peaks (n=16) or the number of peaks (n=11)
(Table 1). Differences in peak intensities were mostly due to the
instrument settings. The paired laboratories came to a consensus
conclusion upon re-analysis of their data, after taking into
account this instrument-related bias, with the balance between
the intensity of the 2 ﬂuorochromes differing in a systematic
fashion between laboratories (Fig. 2A). When 2 laboratories
found a different number of peaks for a given PCR assay
(Fig. 2B), it was analyzed by a third laboratory (Paris-Pitié) and
the proﬁle found in 2 out of 3 laboratories considered to be the
consensus one (see below).
Of note, neither type of discrepancies (number or intensity of
peaks) caused a change of conclusion for the clonality status,
since they only concerned the number of rearranged alleles
(clonal population with either mono-allelic or bi-allelic rear-
rangements) or the presence of a minor peak of unknown
signiﬁcance in addition to a major clonal peak. Inter-laboratory
discrepancies were solved for all these 27 samples after this ﬁrst
step of data reviewing, although there was clear inter-laboratory
heterogeneity in the relative signal intensity of ﬂuorochromes.Inter-assay comparison of the GeneScan proﬁles for
the 3 PCR assays
The 3 PCR assays were then compared based on the consensus
proﬁle for each sample. Results were concordant between the 3
PCR assays in 155/239 cases (65%). Among the 84 remaining
samples, the one “outlier” PCR assay was considered to be
discordant with the other 2.
In 61/84 samples this discordance had no impact on the overall
interpretation. As detailed in SDC Figure 1 (Supplemental Digital
Content, http://links.lww.com/HS/A35), such discrepancies in-
cluded bi-allelic vs mono-allelic rearrangement (45/61 cases) or
cases with additional minor peaks (16/61), all of which were seen
with the TRG-2T-2F assay. The outlier assay was IVS-1T-1F in
26 cases, TRG-2T-2F in 20 cases, and TRG-1T-2F in 15 cases.
Overall, the 3 PCR assays provided similar conclusions for 216
samples (90%).
For the 23 other samples (10% of the cohort), the discordant
results between PCR led to a change of conclusion depending on
which assay was considered (SDC Fig. 1, Supplemental Digital
Figure 2. Inter-laboratory discrepancies regarding peak intensities in the TRG-1T-2F assay. (A) Difference of the green dye peak intensity (arrow)
compared to the blue one. (B) Discrepancy regarding the detection of the blue dye peak (arrow). ALCL, anaplastic large-cell lymphoma.
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into 4 categories: clonal vs polyclonal (n=1), minor clonal vs
polyclonal (n=7), clonal vs oligoclonal (n=11) and minor clonal
vs minor oligoclonal (n=4) (Table 2 and SDC Table 2,
Supplemental Digital Content, http://links.lww.com/HS/A35).
All but one of the reactive samples were concordant between the 3
PCR assays. Only 1 PTCL sample (DE-002) displayed a
signiﬁcant change of conclusion, switching from polyclonal to
clonal. Of note, this case had previously been shown to have a
clonal TRB gene rearrangement pattern.24 Taken together,
the outlier discordant assay was IVS-1T-1F in 10 cases, TRG-1T-
2F in 9 cases and TRG-2T-2F in 4 cases (SDC Fig. 1 and
SDC Table 2, Supplemental Digital Content, http://links.lww.
com/HS/A35).Technical improvements of the EuroClonality
TRG-1T-2F PCR assay
Given that a frequent source of discordant results occurring both
in inter-laboratory TRG-1T-2F duplicates (Fig. 2) and between
the 2 one-tube assays (SDC Fig. 1, Supplemental Digital Content,Table 2
Discrepancies between the interpretation of TRG-2T-2F, TRG-1T-2F, a
the conclusion according to disease category
AITL n=42 ALCL n=48 PTCL n=67
Clonal vs polyclonal 0 0 1
Minor clonal vs polyclonal 3 0 0
Clonal vs oligoclonal 1 0 7
Minor clonal vs oligoclonal 1 1 0
Total 5 1 8
∗
Others: Enteropathy-associated T-cell lymphoma, Sezary syndrome, mycosis fungoides, T-cell lymphoblas
cutaneous lymphomas.
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; PTCL, peripheral T-cell ly
Concordant results for a given PCR (clonal or polyclonal for instance) between the 2 laboratories regard
4http://links.lww.com/HS/A35) concerned the number of domi-
nant clonal peaks (1 vs 2), we investigated the basis of these
discrepancies. This resulted from consistent differences in the
balance between the 2-color ﬂuorescent PCR products (Fig. 2).
We, therefore, changed to single ﬂuorescent (FAM) labeling of
both TRGJG1/2 and TRGJP1/2 primers. Another possible
explanation for the difference in peak number between the
IVS-1T-1F and TRG-1T-2F assays was the lack of a TRGJP
primer in the latter. To test this hypothesis, a modiﬁed TRG-1T-
JPgr assay, which included a differently labeled (HEX/green)
TRGJP primer, was tested together with the initial TRG-1T-2F
and the IVS-1T-1F assays by 2 laboratories (Paris-Pitié, Paris-
Necker) on an additional series of 19 DNA samples (SDC
Table 3, Supplemental Digital Content, http://links.lww.com/HS/
A35). These cases were selected from local archives for the
presence of canonical (n=12) or pathological (n=7) TRGJP
rearrangements previously identiﬁed with in-house multiplex
TRG PCR assays including a TRGJP primer. As expected, all
cases displayed pathological or canonical TRGJP rearrangements
that were not detected by the initial TRG-1T-2F PCR (data not
shown), demonstrating the lack of cross-ampliﬁcation of TRGJPnd IVS-1T-1F PCR assays and their consequences with respect to
T-LGL n=25 T-PLL n=26 Others
∗
n=11 Reactive n=20
0 0 0 0
3 0 0 1
2 1 0 0
2 0 0 0
7 1 0 1
tic lymphoma, T-cell acute lymphoblastic leukemia, autoimmune lymphoproliferative syndrome, primary
mphoma; T-LGL, T-cell large granular lymphocytic leukaemia; T-PLL, T-cell prolymphocytic leukaemia.
ing the categories listed were observed for all other cases.
(2019) 3:3 www.hemaspherejournal.comrearrangements by the TRGJ1/2 or TRGJP1/2 primers. For the 7
cases with a pathological TRGJP rearrangement, the new TRG-
1T-JPgr assay did not change the clonality status since all of them
also had a second clonal non-TRGJP rearrangement, which was
clearly detected by the initial TRG-1T-2F assay. The IVS-1T-1F
PCR also ampliﬁed both alleles in these cases.
One potential risk of including the TRGJP primer within a
single color, single Gaussian distribution as developed by IVS
could be the erroneous identiﬁcation of a canonical TRGV9-
TRGJP rearrangement as evidence of a pathological clonal
population. However, this did not prove to be the case, since the
12 samples with non-malignant TRgd populations did not
generate clonal peaks upon testing with the IVS-1T-1F PCR
assay. In contrast, we found that the dual-labeled TRG-1T-JPgr
proﬁles with the canonical rearrangements outside the Gaussian
curve could sometimes be difﬁcult to interpret (SDC Fig 2,
Supplemental Digital Content, http://links.lww.com/HS/A35)
and inter-laboratory comparison showed striking differences in
the relative intensity of the HEX- and FAM-labeled PCR
products, whereby one laboratory under-estimated and the other
over-estimated the TRGJPgr repertoire (Fig. 3).
This TRG-1T-JPgr assay was then further tested on 17 of the
26 cases associated with an extra peak with IVS-1T-1F compared
to TRG-1T-2F (but with no discrepancy for overall conclusion)
(SDC Fig 1, Supplemental Digital Content, http://links.lww.com/
HS/A35). Only one sample (NL-088, a PTCL) showed a TRGJP
rearrangement (Fig. 4), indicating that the vast majority of
discrepancies were not due to the absence of the TRGJP primer in
the initial TRG-1T-2F assay. Of note, NL-088 also demonstrated
a second weaker non-TRGJP clonal peak. Taken together, the
risk of potential false-positive results generated by inclusion of aFigure 3. Proﬁles of the TRG-1T-JPgr PCR assay in two cases (A and B)
rearrangements. Difference in ﬂuorochrome intensity between two laboratories (to
green dye in the second laboratory (middle panel). In the bottom panel, proﬁles of th
(in green) are indicated by arrows.
5TRGJPgr primer generating larger PCR products was considered
to outweigh the negligible risk of false-negative results when
using a TRGmultiplex which does not allow detection of TRGJP
rearrangements.
In addition to this primer evaluation, a variety of parameters
(annealing temperature, dNTPs, magnesium concentration, type
of thermocycler, etc.) were investigated. This identiﬁed the
dNTPs source as a major determinant causing discrepant results
in the size and ultimately the number of clonal peaks detected
(Fig. 5). Discordance occurred in 12/28 (43%) samples tested (see
below) but was solved when using dNTPs from the same
commercial source. A ﬁnal, optimized TRG-1T-1F PCR assay
taking all these parameters into account and devoid of a TRGJP
primer was then adopted, as described in the Materials and
Methods section. It differed from the TRG-1T-2F essentially by
use of a single ﬂuorochrome for TRGJ primers and
optimized dNTPs.
Evaluation of the optimized EuroClonality TRG-1T-
1F PCR assay
The optimized TRG-1T-1F assay was evaluated on 28 samples
with sufﬁcient available material from the original cohort of 60
samples which had demonstrated clear discrepancies between the
number of peaks detected with the initial TRG-1T-2F and IVS-
1T-1F assays (SDC Fig 1, Supplemental Digital Content, http://
links.lww.com/HS/A35). This comparison was performed in 3
laboratories (Paris-Pitié, Paris-Necker, Erasmus MC) and the
combined results are shown in Table 3.
Of the 17 samples that initially had an extra peak in the IVS-
1T-1F assay, all but 2 (DE-167 and NL-088) now displayed thefrom a separately selected cohort of samples with canonical TRG-JP
p and middle panels) identiﬁes a potentially misleading over-ampliﬁcation of the
e IVS-1T-1F PCR assay are shown for reference. Canonical JP rearrangements
Figure 4. Genescan proﬁles of case NL-088 (PTCL) displaying a clonal TRGJP rearrangement. (A) IVS-1T-1F PCR assay with 2 clonal peaks. It is not
possible to identify which peak corresponds to TRGJP rearrangement with this PCR; (B) TRG-1T-JPgr PCR assay with a TRGV-TRGJ rearrangement in blue and a
pathological TRGJP rearrangement in green.
M. Armand et al. A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell Clonalitysame number of alleles between TRG-1T-1F and IVS-1T-1F.
They included 3 cases (ES-127, ES-206, NL-096) with 2 virtually
overlapping peaks in the TRG-1T-1F GeneScan proﬁle (Fig. 6A)
and 2 (DE-084 and DE-086) which were initially classiﬁed as
polyclonal with the TRG-1T-2F while IVS-1T-1F showed 1 or 2
minor peaks above the polyclonal background. These minor
peaks became apparent with the deﬁnitive TRG-1T-1F PCR
(Fig. 6B). Since the NL-088 discrepancy was due to the absence of
a TRGJP primer in the TRG-1T-2F PCR mix (Fig. 4), only one
case (DE-167) remained truly discordant.
Conversely 11 samples initially had an extra peak with TRG-
1T-2F compared to IVS-1T-1F. In contrast to the previous
category, the use of the TRG-1T-1F PCR mix did not change
these discrepancies. However, upon careful examination of the
IVS-1T-1F GeneScan proﬁles, 6 cases had 2 overlapping peaks
(Fig. 6C). As such, only 5 of the 11 cases had true discordant
proﬁles (Table 3).
Overall, 7/28 tested samples remained discordant between the
2 one-tube assays with (i) a second allele not being detected by the
TRG-1T-1F assay in 2 samples (DE-167 and NL-088) and by the
IVS-1T-1F assay in 4 samples (DE-063, DE-098, DE-231, GBS-
124), and (ii) a clonal, mono-allelic rearrangement in a PTCL
sample (DE-002) detected by the TRG-1T-1F but not the IVS-1T-
1F assay (Table 3 and Fig. 7). As mentioned above, this case was
demonstrated to be clonal by analysis of the TRB locus 24. For
sample NL-088, with 2 clonal rearrangements with the IVS-1T-
1F PCR, the lack of detection of the second clonal peak by the
TRG-1T-1F PCR was due to the absence of a TRGJP primer in
this assay (Fig. 4). Therefore only 1 of these 7 samples (DE-002)6was associated with a conclusion discrepancy (clonal vs
polyclonal).
Since only 7 (25%) of the 28 discordant DNAs analyzed with
the optimized TRG-1T-1F PCR remained discordant, if we
extrapolate this to the total 60 discordant samples, we can
estimate an overall 6% discordancy rate (15/239) from the initial
EuroClonality cohort between the optimized TRG-1T-1F and
IVS-1T-1F PCR.
In conclusion, the excessive dispersion of the two-tube TRG-
2T-2F PCR generated minor peaks, with a risk of false-positive
results. TRG-1T-1F and IVS-1T-1F assays gave comparable
results, with a slightly more dispersed multiplex in the TRG-1T-
1F assay, leading to a lower risk of superposition of biallelic
clonal rearrangements, and an intentional failure to detect both
canonical and clonal TRGJP rearrangements.Discussion
The assessment of T-cell clonality is often based on the molecular
analysis of TR gene rearrangement patterns, as in contrast to B
cell proliferations, one cannot rely upon the immunophenotypic
detection of “monotypic” TR chain restriction. Interpretation of
TR clonality is, however, often complicated by detection of minor
clones which can reﬂect perturbations of the immune repertoire
rather than neoplastic T-cell populations.7–9,11,13,14
The initial TRG-2T-2F PCR assay was designed to allow both
clonality detection and partial VJ typing for target identiﬁcation
in MRD strategies, with signiﬁcant dispersion of 8 sub-
repertoires according to TRGV and TRGJ usage. This inevitably
Figure 5. Impact of dNTP reagents on GeneScan proﬁles. TRG-1T-2F
PCR assay proﬁles of sample DE-191 (T-LGL), analyzed in 3 laboratories (A, B
and C) using the same PCR conditions, except for the dNTP source.
Laboratories B and C used the same dNTP reagents resulting in a single peak,
while laboratory A used dNTP reagents from a different provider (Thermo-
Fischer), with the PCR proﬁle displaying 2 clonal peaks.
Table 3
Evaluation of the EuroClonality TRG-1T-1F assay on 28 of the 60
samples initially showing a discrepancy in the number of alleles
between IVS-1T-1F and TRG-1T-2F assay
Case Disease category IVS-1T-1F TRG-1T-2F TRG-1T-1F
Discrepancy: extra peak in the IVS-1T-1F assay (n=17)
FR-040 PTCL 2R 1R 2R
ES-127 T-LGL 2R 1R 2R
∗
ES-134 T-LGL 2R 1R 2R
GB-24 T-LGL 2R 1R 2R
NL-185 ALCL 2R 1R 2R
DE-167 (‡) T-LGL 2R 1R 1R
DE-166 PTCL 2R 1R 2R
GBS-142 AITL 2R 1R 2R
FR-244 ALCL 2R 1R 2R
DE-191 T-LGL 2R 1R 2R
ES-202 PTCL 2R 1R 2R
ES-206 PTCL 2R 1R 2R
∗
NL-116 AITL 2R 1R 2R
NL-096 ALCL 2R 1R 2R
∗
NL-088 (‡,†) PTCL 2R† 1R 1R
DE-084 AITL P + 1R P P + 1R
DE-086 AITL P + 1 or 2R P P + 2R
Discrepancy: extra peak in the initial TRG-1T-2F assay (n=11)
DE-063 (‡) AITL 1R 2R 2R
DE-098 (‡) ALCL 1R 2R 2R
DE-133 PTCL 1R
∗
2R 2R
DE-190 T-LGL 1R
∗
2R 2R
DE-231 (‡) T-PLL 1R 2R 2R
DE-092 AITL 1R
∗
2R 2R
FR-081 AITL 1R
∗
2R 2R
FR-167 PTCL 1R
∗
2R 2R
FR-210 AITL 1R
∗
2R 2R
GBS-124 (‡) ALCL 1R 2R 2R
DE-002 (‡) PTCL P P + 1R P + 1R
P: polyclonal; R: rearrangement.
∗
Overlap of 2 very close peaks.
† Including a TRGJP rearrangement.
‡ Cases that remain discordant between IVS-1T-1F and TRG-1T-1F assays.
(2019) 3:3 www.hemaspherejournal.comled to the higher risk of false-positive results, particularly for the
minor sub-repertoires and in samples with few T lymphocytes.
We therefore developed a preliminary single-tube TRG-1T-2F
PCR optimized for clonality assessment, including in FFPE
samples. This assay was compared to the original TRG-2T-2F
PCR and the commercial IVS-1T-1F kit, in a multi-center study
including 10 EuroClonality laboratories, on 239 samples from
the previous BIOMED-2 report.24 Results showed that the vast
majority (86%) of samples were concordant, but 14% displayed
discrepant proﬁles, including after panel review.
Additional peaks were often observed with the TRG-2T-2F
system due the dispersion of PCR size products, particularly for7tube B, where seemingly clonal peaks could appear due to the low
number of T-cells using more rare TRGV-TRGJ combinations.
Discrepancies between PCR assays were also due frequently to
the variable presence of a second clonal peak resulting from
clear inter-laboratory differences in detection of the relative
intensity of the 2 ﬂuorochromes, presumed to be due to
differences in instrument choice and settings. In order to avoid
this problem, it was considered preferable to use a single
ﬂuorochrome, as is the case with the IVS-1T-1F PCR and our
optimized TRG-1T-1F assay. These conclusions are in keeping
with previous studies, 20,25,26 in favor of homogeneously labeled
PCR products with limited size range. Cushman-Vokoun et al.
reported that their one-tube assay was as sensitive but more
speciﬁc than the BIOMED-2 TRG-2T-2F, and underlined the
difﬁculty of interpreting clonal peaks when rearrangements are
distributed over several separate areas.20 By splitting exploration
of the TRG locus over 4 tubes, Patel et al. conﬁrmed the risk of
overinterpretation of “pseudoclonality” and favored the combi-
nation of several assays, including TRB assessment.25 The
concern with multi-distribution design assays was also under-
lined by Kansal et al. comparing the TRG-2T-2F assay with a
next-generation sequencing-based one-tube assay. 26
Figure 6. Examples of discrepancies between one-tube TRG PCR assays. (A) Case ES-206 (PTCL) with bi-allelic rearrangements with the IVS-1T-1F PCR
(left) and apparently only 1 rearrangement but possibly with 2 overlapping peaks in the TRG-1T-1F PCR (right). (B) Case DE-086 (AITL) with a polyclonal proﬁle with
the TRG-1T-2F PCR (left), and 2 peaks on a polyclonal backgroundwith both the IVS-1T-1F (middle) and TRG-1T-1F assays (right). (C) Case DE-133 (PTCL) with bi-
allelic rearrangements with TRG-1T-1F PCR (right) and only 1 rearrangement but possibly with 2 overlapping peaks in the IVS-1T-1F PCR (left). Red peaks
correspond to size markers.
M. Armand et al. A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell ClonalityFurther evaluation showed that most discrepancies were due to
failure to amplify the second clonal peak with PCRs using
inappropriate dNTPs, demonstrating that minor technological
modiﬁcations can signiﬁcantly impact on clonality proﬁles. The
role of dNTPs as a critical parameter in multiplex PCR has been
previously reported,27,28 with these components appearing to be
particularly sensitive to repeated thawing/freezing cycles. With
the optimized TRG-1T-1F assay, the concordance rate between
the 2 one-tube TRG PCR assays reached 94%. The capacity of
the EuroClonality group to perform widespread, multicenter
testing allows identiﬁcation of minor details in technical
parameters which can lead to discordant inter-laboratory results,
as demonstrated here for the balance between ﬂuorochromes and
dNTP usage.
The simplicity of the TRG combinatorial repertoire allows
inclusion of primers for all rearrangements with a limited risk of
false-negative results. However, there is a risk of a false-positive
result in the presence of canonical TRGV9-JP rearrangements,
which generate PCR products of uniform size but which cannot
be easily detected in single color multiplex strategies with
overlapping repertoires. The TRGJP gene-speciﬁc primer was,
therefore, intentionally omitted from the TRG-2T-2F and TRG-
1T-1F primer sets. This led to the expected failure to detect a
clonal TRGJP rearrangement in one of the 239 samples, in
contrast to the IVS-1T-1F assay, which does include a TRGJP
primer that generates rearranged amplicons overlapping with the
other sub-repertoires. We, therefore, tested a modiﬁed TRG-1T-
JPgr PCR which included a TRGJP primer generating slightly
larger PCR products. This proved, however, to be potentially
problematic since it was not easy to distinguish canonical from8pathological TRGJP rearrangements. In order to avoid misinter-
pretation of these rearrangements in not very experienced
laboratories, we therefore chose to remove the TRGJP primer
from the ﬁnal, optimized, TRG-1T-1F assay. Cushman-Vokoun
et al included a TRGJP primer in their assay, which places TRGV-
JP rearrangements in the middle of the Gaussian curve, thereby
decreasing -but not eradicating- the risk of false positivity.20 They
tested it on a relatively limited cohort of 40 samples, and found a
good speciﬁcity, with no false positives. Presuming that this PCR
assay is similar or identical to the IVS-1T-1F PCR used here, we
conﬁrmed the absence of false positives in all 12 DNA samples
with canonical TRGJP rearrangements. We consider, however,
that this at least theoretical risk outweighs the advantage of
including a TRGJP primer, except in experienced laboratories. If
a TRGJP primer is to be used, it should be one which has been
shown to give satisfactory results when placed within the
Gaussian distribution, as in Cushman-Vokoun et al, or which has
been placed outside the Gaussian curve and differentially
labelled, as in Derrieux et al.29 Indeed, in experienced
laboratories, the identiﬁcation of canonical VG9-JP rearrange-
ments can provide a useful “positive control”. They are
essentially detected in peripheral blood, so the potential risk of
false positive results in tissue diagnostics is limited. In our series,
which included both blood and tissue samples, only 1/239 (0.4%)
was found to have a clonal TRGJP rearrangement, and this case
displayed also a second, albeit minor, clonal peak. Considering
that biallelic rearrangements are reported in more than half of T-
cell malignancies, and TRGJP rearrangements in about 3% of
cases,21 exclusion of this primer will lead to a very low risk of
false-negative results. Furthermore, in cases with unexpected
Figure 7. GeneScan proﬁles of cases with discrepancies between IVS-1T-1F (left) and TRG-1T-1F (right) assays. Regarding case NL-088, the TRGV-
TRGJ rearrangement was seen in both PCRs but the TRGV-TRGJP rearrangement was not detected with the TRG-1T-1F PCR, due to the absence of a TRGJP
primer, in contrast to the assay in Figure 4. It is not possible to determine which peak corresponds to the TRGJP rearrangement in the IVS-1T-1F PCR, as the primer
information is not provided in the IVS TRG V2.0 kit assay.
(2019) 3:3 www.hemaspherejournal.comnegativity when a clonal T-cell proliferation is strongly suspected,
TRG clonality analysis should be complemented by TRB
clonality evaluation, as recommended by the EuroClonality/
Biomed2 guidelines.15,16,249One-tube TRG PCR assays present several advantages relative
to the two-tube TRG-2T-2F assay, including simplicity, reduced
amount of DNA, ease of interpretation, lower risk of false-
positive results and improved applicability to DNA extracted
M. Armand et al. A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell Clonalityfrom FFPE ﬁxed samples due the small size of the amplicons.
Unfortunately, many (19/28) of the FFPE samples from the initial
Biomed2 cohort were degraded, limiting the value of the analysis
of the remaining 9 FFPE samples. Derrieux et al. have, however,
recently demonstrated the superiority of a TRG-1T-JPgr variant
(with NED labeling of the TRGJP primer) compared to an in-
house 2-tube TRG.29 All these advantages are shared between the
IVS-1T-1F and the TRG-1T-1F assays, as they gave largely
comparable results. The 2 main differences between the proﬁles
generated by these PCR systems are (i) the slightly more dispersed
Gaussian distribution of the TRG-1T-1F PCR (see Fig. 1) and (ii)
the aforementioned inclusion of a TRGJP primer in the IVS-1T-
1F assay. As could be anticipated from the smaller Gaussian size
distribution of the IVS-1T-1F PCR, a small number of clonal
samples (15/239 in this series) appeared to have a mono-allelic
rearrangement using this assay but bi-allelic rearrangement with
the TRG-1T-1F, usually due to superposition of both clonal
products in the IVS-1T-1F PCR. This is not, however, a practical
problem in standard hematopathology practice.
Several studies have reported that high-throughput sequencing
methods can be used for T-cell clonality determination.26,30–32
These techniques are currently more labor-intensive, longer and
expensive. They also require dedicated bioinformatics pipelines
and lack standardization for clinical applications. Conventional
assays based on PCR and capillary electrophoresis therefore still
have a place of choice in the molecular diagnostic tools for
lymphoid clonality assessment, at least for the near future.
In conclusion, we describe a new simple, robust multi-center
validated single-tube TRG PCR assay, which will lead to greater
inter-laboratory reproducibility. It shows similar performance to
the commercial one-tube IVS TRG assay when compared to the
original two-tube TRG-2T-2F PCR, thus validating the use
of both the EuroClonality TRG-1T-1F and IVS-1T-1F assays
in T-cell clonality assessment, when tested over a wide range of
T-cell malignancies. It remains possible that one or other 1T-1F
(IVS or EuroClonality TRG) PCR may prove to be preferable
in particular T lymphoid malignancies and they may be
complementary.Materials and methods
Primer design of the initial one-tube EuroClonality
TRG assay
The EuroClonality/BIOMED2 one-tube preliminary system
(TRG-1T-2F) consisted of a single PCR reaction with all 4
TRGV primers (TRGV1f, TRGV9, TRGV10, and TRGV11) and
2 TRGJ primers: TRGJ1/2 and TRGJP1/2. As for the original
two-tube EuroClonality/BIOMED-2 (TRG-2T-2F) assay, these
reverse TRG-1T-2F primers were initially labeled with different
ﬂuorochromes, with TRGJ1/2 HEX-labeled (green) and
TRGJP1/2 FAM-labeled (blue), but in the ﬁnal assay (TRG-
1T-1F) only one-color labeling (FAM) was retained for both
primers (see below). The sequences of the primers and their
positions on the TRGV and TRGJ genes compared to TRG-2T-
2F assay are depicted in SDC Table 4 (Supplemental Digital
Content, http://links.lww.com/HS/A35).
The primers were ﬁrst tested and validated in Paris-Necker
Hospital, then centrally produced and aliquoted in Erasmus MC,
Rotterdam to ensure that all participating laboratories used
identical primers. Of note, the sequences of the primers used in
the IVS-1T-1F PCR assay (T-Cell Receptor Gamma Gene
Rearrangement Assay 2.0 kit, www.Invivoscribe.com) are not10available. It is, however, noteworthy that the TRG-1T-2F, TRG-
1T-1F, and TRG-2T-2F assays do not include a TRGJP primer,
whereas the IVS kit does.Sample collection
The 261 samples (233fresh/frozen and 28 FFPE) used in this
study had been previously collected and thoroughly evaluated for
T-cell clonality within the work packages of EuroClonality/
BIOMED-2 Concerted Action BMH4 CT98–3936.16,24,33 DNA
aliquots were taken from archival material collected and
analyzed in these BIOMED-2 studies. From this initial collection,
22 samples were later excluded because of poor DNA quality as
evidenced by the absence of ampliﬁcation with all PCR assays. A
total of 239 samples (including 230fresh/frozen and 9 FFPE) with
adequate DNA quality were ﬁnally retained for a two-by-two
comparative analysis representing true duplicates by the 10
participating laboratories (AP-HP, Paris-Necker; AP-HP, Paris-
Pitié; AP-HP, Paris-Saint-Louis; AZ Delta, Roeselare; HMDS,
Leeds; Charite, Berlin; UniKiel, Kiel; IPO-Lisboa, Lisbon;
Radboud UMC, Nijmegen; Erasmus MC, Rotterdam). The
samples included 42 angioimmunoblastic T-cell lymphoma
(AITL), 48 anaplastic large-cell lymphoma (ALCL), 26 T-cell
prolymphocytic leukemia (T-PLL), 25 T-cell large granular
lymphocytic leukemia (T-LGL), 67 peripheral T-cell lymphoma
(PTCL), 11 other T-cell malignancies (1 Enteropathy-associated
T-cell lymphoma, 1 Sezary syndrome, 1 mycosis fungoides, 1 T-
cell lymphoblastic lymphoma and 3 T-cell acute lymphoblastic
leukemia (T-ALL), 2 autoimmune lymphoproliferative syndrome
(ALPS), 2 primary cutaneous lymphomas) as well as 20 reactive
samples. The vast majority of AITL, ALCL, PTCL, AILD and
reactive samples were from fresh-frozen tissue and the T-PLL, T-
LGL and T-ALL/LBL samples were from blood or bone marrow.
Four fresh-frozen skin and one gut biopsies were also analyzed.
Histopathological categories were those established by a panel
review of experienced hematopathologists at the time of the
BIOMED-2 studies, as speciﬁed in the initial publications.16,24,33
An additional 19 clinical samples submitted for clonality analysis
from patients from Paris-Pitié and Paris-Necker hospitals were
added speciﬁcally since they had a known TRGJP rearrangement,
as detected by in-house multiplex PCR assays. All samples had
been obtained with informed consent from the patients according
to each participating institution.Cell lines
Seven cell lines (HSB-2, Jurkat, RPMI 8402, CCRF-CEM, HPB-
ALL, MOLT-3, and SU-DHL-1) obtained from commercial
sources (https://www.atcc.org; https://www.dsmz.de) and known
to be positive for TRG rearrangements were used as positive
controls. To assess the sensitivity of the PCR assays, the DNA of
each cell line was diluted at 10%, 5%, and 1% in peripheral
blood lymphocytes DNA from a healthy donor.PCR studies
All PCR reactions were carried out using 50 ng of DNA. For
ampliﬁcations with TRG-1T-1F and TRG-2T-2F primers, the
PCR reactions were largely performed according to the Euro-
Clonality/BIOMED-2 protocol.16 Based on the present work, we
propose an optimized TRG-1T-1F PCR assay. The reaction
conditions were set for a ﬁnal volume of 25ml with 2.5ml of ABI
(2019) 3:3 www.hemaspherejournal.comGold Buffer 10X, 1U of AmpliTaq Gold (ThermoFischer
Scientiﬁc, Waltham, MA) and 5 pmol of each primer. MgCl2
and dNTP (ThermoFischer Scientiﬁc) were used at a ﬁnal
concentration of 2.5mM and 200mM respectively. Cycling
conditions started with a ﬁrst step at 94°C for 10 minutes
followed by 35 cycles including denaturation (1 minute at 94°C),
annealing (1 minute at 60°C), extension (1.5 minute at 72°C) and
a ﬁnal extension at 72°C for 10 minutes. PCR reactions using the
IVS-1T-1F assaywere performed according to themanufacturer’s
recommendations. For all systems, PCR products were analyzed
by GeneScan proﬁling according to the EuroClonality recom-
mendations (www.euroclonality.org).16 Brieﬂy, cases were called
clonal when displaying 1 or 2 dominant peaks with no or
weak polyclonal background, and oligoclonal when there were
3 or more peaks. They were considered as displaying minor
clonal or minor oligoclonal proﬁles when clonal peaks
(respectively 1–2, or 3 or more) were observed on a polyclonal
background, but with a clonal peak height a least twice that of the
polyclonal background.34 Results were reported according to
EuroClonality guidelines.15Organization of the workﬂow and review of data
A total of 10 molecular diagnostic laboratories from 6 European
countries participated in the validation study. Each DNA sample
was tested with the 3 PCR systems by 2 different laboratories.
Each paired laboratory received the same 50 to 55 DNA samples
to mimic duplicate analysis. Data were ﬁrst compared between
paired laboratories. Some discrepant results, due to sample
inversion, different instrument settings or divergent interpreta-
tion were solved at this stage. All of the revised data including
GeneScan proﬁles and scoring sheets were then collected in one
center (Paris-Pitié) and reanalyzed. When agreement could not be
obtained between the paired laboratories regarding the molecular
proﬁle for a given PCR assay, the sample was sent to Paris-Pitié
laboratory for a third evaluation with the discordant PCR assay.
Thus, the ﬁnal interpretation for these cases included similar
duplicate results from at least 2 of the 3 laboratories, which was
considered to be the consensus proﬁle.
The next step of the data review concerned the inter-assay
discrepancies per sample. Discrepant results between PCR
systems could lead to change of conclusion. Each time, the
outlier PCR system was reported. Inter-assay discrepancies
could also be consequence-free, that is, when a clonal
population was found to have a mono-allelic rearrangement
with one PCR and bi-allelic rearrangements with another, or
when a minor clone was found in addition to a strong clonal
rearrangement with one PCR while only the major clone was
seen with another PCR.
EuroClonality assay optimization and
complementary cohort
An adapted one-tube assay (TRG-1T-JPgr) was used to evaluate
the consequences of including the TRGJP primer in the PCR
assay. It corresponds to a single-tube ﬂuorescent multiplex PCR
adapted from the initial TRG-1T-2F PCR by identical FAM
labeling of the TRGJP1/2 and TRGJ1/2 primers and addition of
an HEX-labeled TRGJP primer (SDC Table 4, Supplemental
Digital Content, http://links.lww.com/HS/A35), adapted from a
similarly modiﬁed EuroClonality assay which varied by 5’NED
labeling of the TRGJP primer.29 The 4 TRGV primers were
identical to those in the TRG-1T-2F assay. The TRGJP reverse11primer was intentionally placed further from the 5’ end of the
TRGJP gene, relative to the positions of the TRGJ1/2 and
TRGJP1/2 reverse primers in order to generate larger, distinctly
labeled PCR products, favoring detection of canonical TRGV9-
TRGJP TRgd repertoires, which appears as a major peak at 207
bp, ﬂanked by minor peaks at 204bp and 210bp (Fig. 1E).
A complementary cohort of 19 stored DNA samples previously
obtained from patients with known TRGJP rearrangements
identiﬁed during routine analysis by in-house TRG PCR assays in
Paris-Pitié (n=9) and Paris-Necker (n=10) was added for the
TRGJP study. These samples were assessed by the IVS-1T-1F and
the TRG-1T-JPgr assay in both Paris-Pitié and Paris-Necker, as
for the initial cohort, using identical reactions and cycling
conditions to the initial EuroClonality TRG-1T-2F assay.
The ﬁnal EuroClonality TRG-1T-1F assay is similar to TRG-
1T-JPgr assay but without the TGRJP primer, and is, as such, a
one-tube, one-color assay. Troubleshooting procedures are
proposed in SDC Table 5 (Supplemental Digital Content,
http://links.lww.com/HS/A35).References
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